XNAS
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | 0.24 | 1.65 | +587.50% | $36.8M | ✅ Beat | +0.79% | +15.59% | — |
| 2026-03-10 | Q4 2025 | -1.04 | -0.58 | +44.23% | $0 | ✅ Beat | -0.64% | +4.80% | +6.51% |
| 2025-11-06 |
| Q3 2025 |
| -0.98 |
| -1.08 |
| -10.20% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.83 | -0.92 | -10.84% | $0 | ❌ Miss | +0.00% | +7.10% | +38.44% |
| 2025-03-20 | Q4 2024 | — | -0.55 | — | $0 | — | -5.48% | -2.58% | +11.73% |
| 2024-03-13 | Q4 2023 | — | -1.67 | — | $0 | — | — | — | — |
| 2023-08-11 | Q2 2023 | -2.80 | -2.80 | +0.00% | $0 | ➖ Inline | +2.64% | -6.91% | -32.87% |
| 2023-05-11 | Q1 2023 | -3.60 | -2.40 | +33.33% | $0 | ✅ Beat | -5.55% | +4.47% | -12.24% |
Showing last 8 quarters.